Previous Article | Next Article 
J Virol, February 1998, p. 1103-1107, Vol. 72, No. 2
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
The Major Site of Phosphorylation within the Rous
Sarcoma Virus MA Protein Is Not Required for Replication
Timothy D.
Nelle,1,
Michael F.
Verderame,2
Jonathan
Leis,3 and
John W.
Wills1,*
Department of Microbiology and
Immunology,1 and
Department of
Medicine,2 Pennsylvania State University
College of Medicine, Hershey, Pennsylvania 17033, and
Department of Biochemistry, Case Western Reserve University
School of Medicine, Cleveland, Ohio 441063
Received 21 July 1997/Accepted 22 October 1997
 |
ABSTRACT |
About one-third of the MA protein in Rous sarcoma virus (RSV) is
phosphorylated. Previous analyses of this fraction have suggested that
serine residues 68 and 106 are the major sites of phosphorylation. As a
follow-up to that study, we have characterized mutants which have these
putative phosphorylation sites changed to alanine, either separately or
together. None of the substitutions (S68A, S106A, or S68/106A) had an
effect on the budding efficiency or infectivity of the virus. Upon
examination of the 32P-labeled viral proteins, we found
that the S68A substitution did not affect phosphorylation in vivo at
all. In contrast, the S106A substitution prevented all detectable
phosphorylation of MA, suggesting that there is only one major site of
phosphorylation in MA. We also found that the RSV MA protein is
phosphorylated on tyrosine, but the amount was low and detectable only
with large numbers of virions and an antibody specific for
phosphotyrosine.
 |
INTRODUCTION |
Rous sarcoma virus (RSV) is known to
contain four phosphoproteins: the
subunit of reverse transcriptase
(RT), integrase (IN), matrix (MA), and nucleocapsid (NC) proteins
(10, 16, 18, 26). The latter two are initially synthesized
as a part of the Gag polyprotein, where they provide functions needed
for the process of budding from the plasma membrane (for a review, see
reference 31). Shortly after a particle is formed,
these proteins (as well as the other products of Gag) are released from the precursor by action of the viral protease (PR), allowing the particles to mature and become infectious.
About one-third of the MA protein found within RSV is phosphorylated
(10). This causes MA to migrate as a doublet during sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), the
slower-migrating band being the phosphorylated species (10). While phosphoamino acid analysis by Lai demonstrated that a majority of
the phosphate is attached to serine (18), it was not until mapping studies by Leis et al. that the putative sites of
phosphorylation were identified as serine residues 68 and 106 (20). However, a biological role for this modification has
not been reported.
We have attempted to confirm the putative sites of phosphorylation in
MA and investigate their role in RSV replication by constructing
mutants which have either one or both changed to alanine. Unexpectedly,
only the serine 106 substitution abolished phosphorylation in the
mature MA protein. Moreover, this phosphorylation was found to be
nonessential for both budding and infectivity. Additionally, a very
small amount of tyrosine phosphorylation was identified on the
wild-type MA protein, leaving open the possibility that other
phosphorylation events might play a role in virus replication.
 |
MATERIALS AND METHODS |
DNAs and cells.
The gag gene used for this study
is from pATV-8, an infectious molecular clone of the RSV Prague C
genome (27). M13mp19P12, a M13mp19 recombinant containing
this gag gene, was used for oligonucleotide-directed mutagenesis and has been described previously (12). RSV
gag alleles were expressed in COS-1 (simian) cells with
pSV.Myr0 (32). To study infectivity, the gag
alleles were cloned either into pBH-RCAN-HiSV (8) for
studies in QT6 (quail) cells or into pJD100 (9) for studies
in TEF (turkey embryo fibroblast) cells. Standard protocols were used
for all DNA manipulations (25).
COS-1 cells were grown in Dulbecco's modified Eagle's medium (GIBCO
Laboratories) supplemented with 3% fetal bovine serum and 7% calf
bovine serum (Hyclone, Inc.). QT6 cells (kindly provided by Paul Bates,
University of Pennsylvania, Philadelphia, Pa.) were cultured in F10
medium (GIBCO Laboratories) supplemented with 10% tryptose phosphate
broth, 5% fetal calf serum, and 1% chicken serum. TEFs were isolated
from fertile eggs (Hudson Farms, Muskogee, Okla. or Clearview Hatchery,
Gratz, Pa.) and propagated in supplemented F10 medium as previously
described (17).
Construction of mutants.
S68A, S106A, and R121L were created
by oligonucleotide-directed mutagenesis with a single-stranded,
uracil-containing template DNA isolated from M13mp19P12 and
oligonucleotides for introducing point mutations at codons 68 (TCG to
GCG), 106 (TCG to GCT), or 121 (CGA to CTA). Mutations were
confirmed by DNA sequencing by the dideoxy method and moved from
the replicative form DNA into the pSV.Myr0 plasmid by transfer of an
SstII fragment. pSV.S68/106A was constructed by moving
the XhoI-EcoRV fragment (and the S106 mutation) from pSV.S106A into pSV.S68A.
All mutations (S68A, S106A, S68/106A, and R121L) were moved from the
pSV.Myr0 plasmids into pBH-RCAN-HiSV and pJD100 by first transferring
their SacI-EcoRI fragments into pSV.G1P
(4). This intermediate step allowed subsequent transfer of
the mutations into the RSV genome with the same upstream
SacI site and the unique downstream HpaI site
obtained from pSV.G1P.
To avoid inadvertent mutations that may arise during the mutagenesis
and cloning steps, multiple independent clones of each mutant were
sequenced and characterized in transfection experiments to be sure they
exhibited the same phenotype.
Transfection and labeling of mammalian cells.
COS-1 cells
were transfected by the DEAE-dextran-chloroquine method as described
previously (2, 32, 33). Plasmid DNAs were digested with
XbaI and ligated at a concentration of 25 µg/ml prior to
transfection. This step removes the bacterial plasmid sequence and
joins the 3' end of gag to the simian virus 40 polyadenylation signal for high-level expression.
Two days posttransfection, COS-1 cells were metabolically labeled with
L-[35S]methionine for 2.5 h (50 µCi,
>1,000 Ci/mmol), as previously described (2, 32, 33). The
cells and growth medium were collected and mixed with lysis buffer
containing protease inhibitors. Gag proteins were collected from the
samples by immunoprecipitation with a rabbit antiserum against whole
RSV (30) by methods previously described (2, 32,
33).
SDS-PAGE.
Proteins were separated by electrophoresis in
SDS-12% polyacrylamide gels, as described before (2, 32,
33). Gels were fixed in a solution of 5% methanol and 7% acetic
acid, and radiolabeled proteins were detected by autoradiography with
Kodak X-Omat AR5 film at
80°C.
Relative amounts of Gag proteins in medium and cell lysate samples were
measured by laser scanning densitometry of fluorograms. The budding
efficiency of each mutant was calculated by dividing the amount of Gag
protein present in the medium sample by the total amount of Gag protein
found in both medium and lysate samples.
Transfection and infection of avian cells.
Recombinants of
pBH-RCAN-HiSV and pJD100 carrying the mutant gag alleles
were initially tested for infectivity by a qualitative method in which
persistent expression of viral proteins is assayed (21).
Because transfected DNA exists transiently, only those mutants that can
integrate their proviral genomes (and therefore are infectious) will
continue to express viral proteins after several passages. DNA clones
that are noninfectious will not spread throughout the culture, and
expression of their viral proteins will be only transient. For these
experiments, duplicate plates of avian (QT6) cells were transfected by
the calcium phosphate method (5, 6). One plate was used to
monitor the transfection efficiency by measuring the level of
Pr76gag expression immediately following the
18-h transfection period. The cells in the second plate were passaged
(1:5) into two plates 2 days posttransfection and then every 3rd day
thereafter. Forty-eight hours after each passage, infectivity was
assessed by measuring expression of Pr76gag.
This was accomplished by labeling with
L-[35S]methionine (100 µCi, >1,000
Ci/mmol) for 2 h, collecting the labeled Gag proteins from cell
lysates by immunoprecipitation with polyclonal anti-RSV serum, and
separating them by SDS-PAGE, as described above.
Focus assays.
Focus assays were performed with the pJD100
recombinants, as previously described (29). Briefly, freshly
harvested virions were normalized by RT activity (4, 9) and
used to infect 60-mm plates of uninfected TEF cells for 2 h.
Immediately following infection, the plates were washed four times
before the addition of 5 ml of a soft agar overlay (29).
Cultures were fed every 3 days with fresh media until foci were clearly
visible and easily countable (14 to 21 days).
Analysis of phosphorylation.
For examining serine
phosphorylation, 100-mm plates of TEFs infected with recombinants of
pJD100 bearing the wild-type (myr0) or mutant Prague C
gag alleles were metabolically labeled with [32P]ortho-phosphate (1 mCi) in 5 ml of
phosphate-free Dulbecco's modified Eagle's medium for 24 h. The
media were collected, and loose cells were removed by centrifugation,
and then the viral particles were allowed to mature at 37°C for
24 h. The mature virions were passed through a syringe-tip filter
(45 µm), pelleted through a 25% sucrose cushion, and dissolved in
loading buffer. The viral proteins were separated by SDS-PAGE and
transferred to nitrocellulose by electroblotting, and
32P-labeled proteins were visualized by autoradiography. To
visualize all the viral proteins, the blots were probed with antiserum
against RSV, and the resulting antigen-antibody complexes were detected by enhanced chemiluminescence (Amersham) as previously described (1).
For detection of tyrosine phosphorylation, 300 µg of sucrose-purified
Prague C RSV was disrupted in gel loading buffer, subjected to
SDS-PAGE, and transferred to nitrocellulose. Phosphotyrosine-containing proteins were detected with PY20, a monoclonal antibody that is specific for phosphotyrosine (Transduction Labs).
 |
RESULTS |
Previous data have suggested that RSV MA is phosphorylated on the
hydroxyl groups of serines 68 and 106. To investigate the importance of
this modification in RSV replication, we constructed mutants in which
either one or both of these residues are changed to alanine (Fig.
1), an amino acid that differs from
serine in lacking the hydroxyl group. To examine the effects of these
substitutions on particle production, the corresponding gag
alleles were introduced into pSV.Myr0, a previously described plasmid
that permits expression and budding of the wild-type Gag protein in
mammalian cells (32). Budding efficiencies were compared to
the parental construct and a mutant, Myr0.dMA4, which is defective for
budding (21). All three serine mutants exhibited budding
efficiencies which were similar to that of the wild type (Fig.
2). While the efficiencies varied
slightly from experiment to experiment, they were typically 5 to 20%
less than that of the control. Such minor differences indicate that
serine phosphorylation is not important for particle release.

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 1.
RSV MA sequence. Serine residues previously reported as
the sites of phosphorylation are denoted by circles. Positions of
tyrosine residues are highlighted with boxes. Numbers refer to the
positions of individual residues with respect to the amino terminus of
MA.
|
|

View larger version (89K):
[in this window]
[in a new window]
|
FIG. 2.
Expression and release of serine mutants. COS-1 cells
were metabolically labeled for 2.5 h with
[35S]methionine 48 h after transfection with the
indicated mutants. Gag proteins were immunoprecipitated from cell and
medium lysates with polyclonal anti-RSV serum, resolved by SDS-PAGE,
and visualized by fluorography. Positions of molecular size markers are
indicated on the right. The positions of the full-length Gag protein
(Pr76gag) and those of its mature cleavage
products are indicated on the left. The heterogeneous MA proteins are
marked by larger brackets. Myr0 and dMA4 are wild-type and negative
controls, respectively.
|
|
To determine whether phosphorylation is essential for infectivity, the
mutations were cloned into pBH.RCAN, a plasmid which carries an
infectious proviral genome and an hygromycin resistance gene in lieu of
the Src-coding sequence normally present in RSV. The infectivity of
these recombinants was tested in quail (QT6) cells. All the mutants
appeared to be infectious, as indicated by both the spread of
hygromycin resistance throughout transfected cultures and the ability
of the mutants to maintain viral protein expression weeks after
transfection (data not shown).
The infectivity of the MA mutants was also assessed with pJD100, a
plasmid which retains the v-src oncogene within the proviral genome (9). Each recombinant was transfected into duplicate plates of QT6 cells. One set of plates was used to monitor transient Gag expression, confirming that all of the transfections had been successful (Fig. 3, transient panel).
The cells in the remaining plates were split (1:5) into two
fresh plates 48 h posttransfection and every 3rd day
thereafter. Attempts were made to immunoprecipitate Gag proteins
from [35S]methionine-labeled cells 48 h after each
passage. By the third passage, expression from the negative
control (pRC.dMA10 [21]) had been lost, but expression
of all of the serine mutants continued (Fig. 3, passage 3).

View larger version (39K):
[in this window]
[in a new window]
|
FIG. 3.
Qualitative analysis of infectivity. Each indicated
clone was used to transfect duplicate plates of QT6 cells. One plate
from each set was metabolically labeled for 2 h with
[35S]methionine immediately following transfection, and
the Gag proteins were collected by immunoprecipitation (Transient). The
remaining plate of cells was passaged 2 days posttransfection and every
3rd day thereafter. On the 3rd day of the third passage, the cells were
metabolically labeled with [35S]methionine, and again the
Gag proteins were collected by immunoprecipitation (Pass 3). Proteins
were separated by SDS-PAGE and visualized by fluorography. Only the
region of the gel containing the Gag precursors is shown. RC.V8 and
RC.MA10 are wild-type and negative controls, respectively. S106A.1 and
S106A.2 are independent clones containing the same mutation.
|
|
The infectivity of each of the MA mutants was quantified in focus
assays. Virus particles were obtained from transfected QT6 cells, the
relative concentrations were measured by RT activity, and equal amounts
were placed on uninfected TEF cells. Dense foci were scored 14 to 21 days later. As summarized in Table 1,
neither the S68A nor the S106A mutation alone had detectable effects on infectivity, while the infectivity of virus harboring both mutations was reduced to only about half that of the wild type.
Before we could conclude that RSV infectivity is independent of serine
phosphorylation of MA, it was necessary to assess the phosphorylation
state of the mutants. This was accomplished by labeling infected TEFs
with H332PO4 as described in
Materials and Methods. Labeled virus was pelleted through a 25%
sucrose cushion and then dissolved in sample buffer. Viral proteins
were separated by SDS-PAGE and subsequently transferred to
nitrocellulose by electroblotting. Visualization of
32P-labeled proteins by autoradiography showed that the
wild-type virus contains two major phosphoproteins of 19 and 12 kDa,
consistent with the sizes of MA and NC, respectively (Fig.
4B, lane 1, bands marked PP1 and PP4).
Two additional phosphoproteins were detected which together accounted
for less than 20% of the incorporated label (Fig. 4B, lane 1, bands
marked PP2 and PP3). The migration of one of these (PP2) is consistent
with a degradation product of MA which lacks the final four amino acids
(23). We suspect that PP3 is also a breakdown product of MA,
since substitutions that block phosphorylation of MA also prevent
detection of this phosphoprotein (see below). The origin of PP5 is not
clear. It migrates faster than the other known viral phosphoproteins
during SDS-PAGE, and its intensity varied in repeats of this
experiment. While this band appears to comigrate with PR under the
SDS-PAGE conditions used here and those used by Lai, clearly it is not PR (18).

View larger version (57K):
[in this window]
[in a new window]
|
FIG. 4.
In vivo phosphorylation. Infected TEFs were labeled with
32P for 24 h. Virus was pelleted through a 25%
sucrose cushion and dissolved in sample buffer. Viral proteins were
separated by SDS-12% PAGE and then transferred to nitrocellulose. (A)
Immunoblot with anti-RSV serum. (B) Autoradiograph of the same blot.
The positions of Gag cleavage products and molecular size markers are
indicated on the left and right, respectively. Phosphoproteins detected
in this experiment are labeled PP1 to PP5 and IN* (predicted to be
phosphorylated IN based on apparent size).
|
|
With regard to the mutants, the S68A substitution appeared to have
little if any effect on the phosphoprotein profile, while the S106A
substitution abolished almost all of the detectable phosphorylation
(Fig. 4B, lanes 2 and 3). The absence of 32P-labeled
proteins for S106A was not due to a sample loading error, because
immunoblot analysis of the same nitrocellulose filter revealed that all
the lanes contained approximately the same amount of protein (Fig. 4A,
lanes 1 to 4). Furthermore, the S106A sample contained a single MA
species which comigrated with the lower band of the wild-type MA
doublet, the position of the unphosphorylated form of MA
(10). These results demonstrate that the major site of
phosphorylation within RSV MA is serine 106 and allow us to conclude
that serine phosphorylation is not important for infectivity.
We were surprised to find that the S106A mutation seems to prevent
almost all of the phosphorylation of the 12-kDa protein (PP4),
previously reported to be NC. This finding could indicate that MA
phosphorylation is a prerequisite for phosphorylation of NC, possibly
through recruitment of a specific kinase or cofactor which is required
for NC phosphorylation. However, it seemed possible that the 12-kDa
phosphoprotein was not NC but was actually a comigrating breakdown
product of phosphorylated MA previously referred to as p19f (23,
28). To explore this possibility, mutants which produce either a
faster- or a slower-migrating MA protein (RC.
MA6 [21] and RC.R121L, respectively) were labeled with
H332PO4 and analyzed as described
above. For both of these mutants, the altered migration of a portion of
the 12-kDa phosphoprotein matched that of the mutant MA species (Fig.
5), indicating that the 12-kDa
phosphoprotein is actually a mixture of phosphorylated p19f and NC
proteins. Since serine phosphorylation is not important for
infectivity, we did not explore this any further.

View larger version (39K):
[in this window]
[in a new window]
|
FIG. 5.
Analysis of pp12 species. 32P-labeled
virions produced from infected TEFs were pelleted through a 25%
sucrose cushion. Following suspension in sample buffer, the viral
proteins were separated by SDS-12% PAGE and transferred to
nitrocellulose. (A) Immunoblot with anti-RSV serum. (B) Autoradiograph
of the same blot. R121L and MA6 contain mutations which cause
MA-related proteins to migrate either slower or faster, respectively,
during electrophoresis. The locations of the wild-type and
slower-migrating forms of p19f are indicated on the left side of panel
A.
|
|
Given the lack of an apparent role for serine phosphorylation, we
wondered whether other minor sites of phosphorylation (such as the
tyrosine phosphorylation found in human immunodeficiency virus [HIV]
MA [14, 15]) might also exist in RSV MA. To explore this possibility, we probed blots of purified RSV with an antibody that
recognizes phosphotyrosine in a manner that is insensitive to the
adjacent amino acids. Three viral proteins were detected (Fig.
6, lanes 3). These proteins correspond to
the positions of the MA-p2 cleavage intermediate, serine-phosphorylated
MA, and MA lacking phosphoserine. Of the three tyrosines contained within the MA sequence (Fig. 1, residues 15, 46, and 155), Y46 is most
likely the site recognized by a protein tyrosine kinase, based on its
surrounding sequences which have characteristics of known tyrosine
phosphorylation sites (24). The lack of detectable phosphotyrosine on the smaller species of MA (including p19f, which
consists of a mixture of two species corresponding to residues 1 to 123 and 1 to 129 [23]) suggests either that these are
derived from MA species lacking phosphotyrosine or that Y155 is
actually the site of modification. Further experimentation will be
required to determine which residue(s) is modified.

View larger version (49K):
[in this window]
[in a new window]
|
FIG. 6.
Detection of tyrosine-phosphorylated MA. (A) Proteins
from sucrose gradient-purified RSV were separated by SDS-12% PAGE,
transferred to nitrocellulose, and probed with an antiphosphotyrosine
antibody and visualized by enhanced chemiluminescence. (B) Later, the
same blot was stripped of antibodies and reprobed with anti-RSV serum.
Lanes: 1, Src-transformed Rat-1 cell extract (positive control); 2, Rat-1 cell extract (negative control); 3, RSV.
|
|
 |
DISCUSSION |
The experiments described in this study identify serine 106 as the
major site of phosphorylation within RSV MA and are in agreement with
recent electronic spray mass spectroscopy measurements of MA,
indicating that the phosphorylated form of MA contains only one
phosphate molecule (23). While it appears that serine 68 is
not a major site of phosphorylation, methods employed in this study are
not sensitive enough to determine whether a small amount of phosphate
(3% or less, as determined by laser scanning densitometry) is attached
to this residue. Likewise, we cannot address the possibility that
serine 68 may be phosphorylated in a transient manner, since labeling
was performed only under steady-state conditions. However, since
phosphorylation of either site is nonessential for virus replication,
this issue seems to be of little significance. Furthermore, infectivity
of the serine mutants was observed in two different cell types (TEF and
QT6) and thus does not appear to have a cell-type dependent function.
Nevertheless, we cannot eliminate the possibility that this region
plays some important role in nature (i.e., in chickens).
pp12 proteins.
The fact that the S106A mutation reduces the
phosphorylation of NC is consistent with phosphorylation of MA being a
prerequisite for phosphorylation of NC. The mechanism by which this
would occur is unclear, but it is possible that modification of MA
induces a conformational change in Gag which then allows NC to be
recognized by a kinase. Alternatively, phosphorylation of serine 106 may be necessary for the recruitment of factors which directly or indirectly promote NC phosphorylation. Regardless of the mechanism, the
need for such a regulatory event is not clear. Although previous studies indicate that the dephosphorylation of NC results in a conformational change and a 100-fold decrease in affinity for RNA
(11, 19), the phosphorylation of NC, like that of MA, can be
prevented without affecting infectivity (12), suggesting that if the phosphorylation of either protein is important, it is not
rate limiting. It is possible that the phosphorylation of both proteins
is fortuitous
the result of Gag proteins assembling into virus
particles in the vicinity of a host of protein kinases on the plasma
membrane.
Why are only a third of the RSV MA molecules phosphorylated?
When MA protein from RSV particles is subjected to SDS-PAGE, it
migrates as a doublet, with the upper band containing the phosphorylated species. Assuming that this band contains only phosphorylated MA and that the lower band contains only
unphosphorylated MA, it has been estimated that approximately one-third
of the MA found in the virion is phosphorylated (10). With
the same assumptions, MA molecules associated with the cell appear to
be phosphorylated at levels similar to that found within the virion, suggesting that phosphorylation occurs either before or during particle
formation. Therefore, at least three possible mechanisms can account
for this partial modification. (i) The responsible kinase is present in
limited quantities or is sequestered in a cellular location that some
Gag molecules bypass. (ii) Gag molecules form multimers before
phosphorylation occurs, thereby limiting access to the internal
molecules. (iii) All Gag molecules may be equally capable of being
phosphorylated, but competition between kinases and phosphatases
determines what portion of the Gag molecules are phosphorylated
(7).
Minor sites of phosphorylation.
While the experiments
presented here show that serine phosphorylation is not needed for
infectivity of RSV, they do not rule out the possibility that other
minor sites of phosphorylation are essential. Recent studies of the HIV
MA protein have suggested that such minor modifications are important.
Specifically, the phosphorylation of a small fraction of MA molecules
(1% percent) on the C-terminal tyrosine enables them to shift from
being membrane associated to being bound to IN within the core of the
virion (14, 15). Once this core is released into a cell, the
phosphorylated MA molecules appear to be able to direct the complex to
the nucleus via its nuclear localization sequence prior to integration,
a feature which may be required by HIV to infect nondividing cells in
some cases (3, 13). As demonstrated here, a minor population of RSV MA also contains phosphotyrosine. While the role of this modification, if any, is unknown at this time, clearly it cannot be the
same as in HIV, since RSV does not infect nondividing cells. Nevertheless, recently published work suggests that the MA protein of
RSV plays a role of some sort during the establishment phase of the
replication cycle (22). Efforts to elucidate this function are currently in progress.
 |
ACKNOWLEDGMENTS |
We thank Anu Raman for creating the point mutations in
M13mp19P12.
This work was supported by NIH grants to T.D.N. (training grant
CA60395), M.F.V. (CA52791), J.L. (CA38046), and J.W.W. (CA47482) and by a grant from the American Cancer Society to J.W.W.
(FRA-427).
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Microbiology and Immunology, College of Medicine, Pennsylvania State University, Hershey, PA 17033. Phone: (717) 531-3528. Fax: (717) 531-6522. E-mail: jwills{at}bcmic.hmc.psu.edu.
Present address: Virology Division, United States Army Medical
Research Institute of Infectious Diseases, Fort Detrick, MD 21702.
 |
REFERENCES |
| 1.
|
Bennett, R. P.,
T. D. Nelle, and J. W. Wills.
1993.
Functional chimeras of the Rous sarcoma virus and human immunodeficiency virus Gag proteins.
J. Virol.
67:6487-6498[Abstract/Free Full Text].
|
| 2.
|
Bennett, R. P.,
S. Rhee,
R. C. Craven,
E. Hunter, and J. W. Wills.
1991.
Amino acids encoded downstream of gag are not required by Rous sarcoma virus protease during Gag-mediated assembly.
J. Virol.
65:272-280[Abstract/Free Full Text].
|
| 3.
|
Bukrinsky, M. I.,
S. Haggerty,
M. P. Dempsey,
N. Sharova,
A. Adzhubel,
L. Spitz,
P. Lewis,
D. Goldfarb,
M. Emerman, and M. Stevenson.
1993.
A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells.
Nature
365:666-669[Medline].
|
| 4.
|
Craven, R. C.,
R. P. Bennett, and J. W. Wills.
1991.
Role of the avian retroviral protease in the activation of reverse transcriptase during virion assembly.
J. Virol.
65:6205-6217[Abstract/Free Full Text].
|
| 5.
|
Craven, R. C.,
D. A. Leure,
C. R. Erdie,
C. B. Wilson, and J. W. Wills.
1993.
Necessity of the spacer peptide between CA and NC in the Rous sarcoma virus Gag protein.
J. Virol.
67:6246-6252[Abstract/Free Full Text].
|
| 6.
|
Craven, R. C.,
D. A. Leure,
R. J. Weldon, and J. W. Wills.
1995.
Genetic analysis of the major homology region of the Rous sarcoma virus Gag protein.
J. Virol.
69:4213-4227[Abstract].
|
| 7.
|
Depaoli-Roach, A. A.,
I. K. Park,
V. Cerovsky,
C. Csortos,
S. D. Durbin,
M. J. Kuntz,
A. Sitikov,
P. M. Tang,
A. Verin, and S. Zolnierowicz.
1994.
Serine/threonine protein phosphatases in the control of cell function.
Adv. Enzyme Regul.
34:199-224[Medline].
|
| 8.
|
Dong, J. Y.,
J. W. Dubay,
L. G. Perez, and E. Hunter.
1992.
Mutations within the proteolytic cleavage site of the Rous sarcoma virus glycoprotein define a requirement for dibasic residues for intracellular cleavage.
J. Virol.
66:865-874[Abstract/Free Full Text].
|
| 9.
|
Erdie, C. R., and J. W. Wills.
1990.
Myristylation of Rous sarcoma virus Gag protein does not prevent replication in avian cells.
J. Virol.
64:5204-5208[Abstract/Free Full Text].
|
| 10.
|
Erikson, E.,
J. S. Brugge, and R. L. Erikson.
1977.
Phosphorylated and nonphosphorylated forms of avian sarcoma virus polypeptide p19.
Virology
80:177-185[Medline].
|
| 11.
|
Fu, X.,
N. Phillips,
J. Jentoft,
P. T. Tuazon,
J. A. Traugh, and J. Leis.
1985.
Site-specific phosphorylation of avian retrovirus nucleocapsid protein pp12 regulates binding to viral RNA. Evidence for different protein conformations.
J. Biol. Chem.
260:9941-9947[Abstract/Free Full Text].
|
| 12.
|
Fu, X. D.,
P. T. Tuazon,
J. A. Traugh, and J. Leis.
1988.
Site-directed mutagenesis of the avian retrovirus nucleocapsid protein, pp12, at serine 40, the primary site of phosphorylation in vivo.
J. Biol. Chem.
263:2134-2139[Abstract/Free Full Text].
|
| 13.
|
Gallay, P.,
V. Stitt,
C. Mundy,
M. Oettinger, and D. Trono.
1996.
Role of the karyopherin pathway in human immunodeficiency virus type 1 nuclear import.
J. Virol.
70:1027-1032[Abstract].
|
| 14.
|
Gallay, P.,
S. Swingler,
C. Aiken, and D. Trono.
1995.
HIV-1 infection of nondividing cells: C-terminal tyrosine phosphorylation of the viral matrix protein is a key regulator.
Cell
80:379-388[Medline].
|
| 15.
|
Gallay, P.,
S. Swingler,
J. P. Song,
F. Bushman, and D. Trono.
1995.
HIV nuclear import is governed by the phosphotyrosine-mediated binding of matrix to the core domain of integrase.
Cell
83:569-576[Medline].
|
| 16.
|
Hizi, A., and W. K. Joklik.
1977.
The beta subunit of the DNA polymerase of avian sarcoma virus strain B77 is a phosphoprotein.
Virology
78:571-575[Medline].
|
| 17.
|
Hunter, E.
1994.
Biological techniques for avian sarcoma viruses.
Methods Enzymol.
58:379-392.
|
| 18.
|
Lai, M. M.
1976.
Phosphoproteins of Rous sarcoma viruses.
Virology
74:287-301[Medline].
|
| 19.
|
Leis, J.,
S. Johnson,
L. S. Collins, and J. A. Traugh.
1984.
Effects of phosphorylation of avian retrovirus nucleocapsid protein pp12 on binding of viral RNA.
J. Biol. Chem.
259:7726-7732[Abstract/Free Full Text].
|
| 20.
|
Leis, J.,
N. Phillips,
X. Fu,
P. T. Tuazon, and J. A. Traugh.
1989.
Phosphorylation of avian retrovirus matrix protein by Ca2+/phospholipid-dependent protein kinase.
Eur. J. Biochem.
179:415-422[Medline].
|
| 21.
|
Nelle, T. D., and J. W. Wills.
1996.
A large region within the Rous sarcoma virus matrix protein is dispensable for budding and infectivity.
J. Virol.
70:2269-2276[Abstract].
|
| 22.
|
Parent, L. J.,
C. B. Wilson,
M. D. Resh, and J. W. Wills.
1996.
Evidence for a second function of the MA sequence in the Rous sarcoma virus Gag protein.
J. Virol.
70:1016-1026[Abstract].
|
| 23.
|
Pepinsky, R. B.,
I. A. Papayannopoulos,
S. Campbell, and V. M. Vogt.
1996.
Analysis of Rous sarcoma virus Gag protein by mass spectrometry indicates trimming by host exopeptidase.
J. Virol.
70:3313-3318[Abstract].
|
| 24.
|
Pinna, L. A., and M. Ruzzene.
1996.
How do protein kinases recognize their substrates?
Biochim. Biophys. Acta
1314:191-225[Medline].
|
| 25.
|
Sambrook, J.,
E. F. Fritsch, and T. Maniatis.
1989.
.
Molecular cloning: a laboratory manual, 2nd ed.
Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
|
| 26.
|
Schiff, R. D., and D. P. Grandgenett.
1980.
Partial phosphorylation in vivo of the avian retrovirus pp32 DNA endonuclease.
J. Virol.
36:889-893[Abstract/Free Full Text].
|
| 27.
|
Schwartz, D. E.,
R. Tizard, and W. Gilbert.
1983.
Nucleotide sequence of Rous sarcoma virus.
Cell
32:853-869[Medline].
|
| 28.
|
Shealy, D. J.,
A. G. Mosser, and R. R. Rueckert.
1980.
Novel p19-related protein in Rous-associated virus type 61: implications for avian gag gene order.
J. Virol.
34:431-437[Abstract/Free Full Text].
|
| 29.
|
Vogt, P. K.
1969.
Focus assay of Rous Sarcoma virus, p. 198-211. In
H. K. and N. P. Salzman (ed.), Fundamental techniques of virology.
Academic Press, New York, N.Y.
|
| 30.
|
Weldon, R. J.,
C. R. Erdie,
M. G. Oliver, and J. W. Wills.
1990.
Incorporation of chimeric Gag protein into retroviral particles.
J. Virol.
64:4169-4179[Abstract/Free Full Text].
|
| 31.
|
Wills, J. W., and R. C. Craven.
1991.
Form, function, and use of retroviral Gag proteins.
AIDS
5:639-654[Medline].
|
| 32.
|
Wills, J. W.,
R. C. Craven, and J. A. Achacoso.
1989.
Creation and expression of myristylated forms of Rous sarcoma virus Gag protein in mammalian cells.
J. Virol.
63:4331-4343[Abstract/Free Full Text].
|
| 33.
|
Wills, J. W.,
R. C. Craven,
R. J. Weldon,
T. D. Nelle, and C. R. Erdie.
1991.
Suppression of retroviral MA deletions by the amino-terminal membrane-binding domain of p60src.
J. Virol.
65:3804-3812[Abstract/Free Full Text].
|
J Virol, February 1998, p. 1103-1107, Vol. 72, No. 2
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Garbitt, R. A., Albert, J. A., Kessler, M. D., Parent, L. J.
(2001). trans-Acting Inhibition of Genomic RNA Dimerization by Rous Sarcoma Virus Matrix Mutants. J. Virol.
75: 260-268
[Abstract]
[Full Text]
-
Callahan, E. M., Wills, J. W.
(2000). Repositioning Basic Residues in the M Domain of the Rous Sarcoma Virus Gag Protein. J. Virol.
74: 11222-11229
[Abstract]
[Full Text]
-
Parent, L. J., Cairns, T. M., Albert, J. A., Wilson, C. B., Wills, J. W., Craven, R. C.
(2000). RNA Dimerization Defect in a Rous Sarcoma Virus Matrix Mutant. J. Virol.
74: 164-172
[Abstract]
[Full Text]